Here is my opinion of what is going on... Nanobeak is the parent company of Vantage Health. Vantage has issued 189M shares. According to VNTH 10K, Nanobeak owns 58%, or 112M shares.
As gdl reported, "Nanobeak Inc is beneficially owned by Jeremy Barbera". However, I do not believe that he owns 100%. I think he own just over 50%. The rest is still owned by MSGI. So Nanobeak is not publicly traded, but it could be someday, if & when there is 1.) a product 2.) there are sales and revenue. Neither of these will happen without the FDA approval.
In any case, it seems that the focus is on getting FDA approval. That opens the way for Vantage to get something to the market, which will have its own obstacles. But, human trails must be completed and FDA must give approval.
Hard to say if human trials have begun or not. I would like to believe the one story that was linked previously, but cannot be sure if the information was accurate. Time will tell. Once FDA has approved the device, then MSGI would have good reason to get re-listed MSGI. Until then, I don’t see any benefit to do so.
In summary, there a lot of outstanding shares of VNTH. MSGI owns 49% of 112M at best, and maybe less. So don’t plan to make much money from VNTH. If MSGI ever gets relisted, they could start to develop some of the other applications for these VOC sensors.
In 100 years, the stock might be worth something. The next few months should shed some light on the road ahead. That is my take on things.
Nitroman over & out.
